Skip to main content

Immune Thrombocytopenia (ITP) Market to reach USD 3.33 Billion by 2026, Increasing Number of Company Mergers to Aid Growth, says Fortune Business Insights

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, Nov. 26, 2019 (GLOBE NEWSWIRE) — The global Immune Thrombocytopenia Market is likely to derive growth from recent advancements in treatment methods of the disease. According to a report published by Fortune Business Insights, titled “ Immune Thrombocytopenia Market Size, Share & Industry Analysis, By Type (Acute Immune Thrombocytopenia, and Chronic Immune thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and Regional Forecast, 2019-2026,” the market was valued at USD 2.99 Billion in 2018, and is projected to reach USD 3.33 Billion by 2026, exhibiting a CAGR of 0.54% during the forecast period.Immune thrombocytopenia is a serious blood disorder that occurs due to physical injuries, infections, deficiencies, and other wounds. The adverse effects of the disease have led to a high emphasis on the research and development of newer drugs and therapeutic procedures associated with the treatment of the disease. Growing emphasis on R&D will attract huge investments and yield better products. The increasing number of product launches, coupled with advancements in betterment of existing products will have a direct impact on the growth of the market tin the coming years. Although there are very few options available for treatment of the disease, advancements in ongoing clinical trials have shown promise.
Browse Complete Report Details with Table of Content and Figures:
https://www.fortunebusinessinsights.com/industry-reports/immune-thrombocytopenia-itp-market-101682

The report segments the market based on disease type, treatment type, and regional demographics. Several aspects of the market have been discussed in detail, with focus on growth drivers, leading product types, and major companies. The report highlights key companies that are operating in the market and projects companies that are likely to lead the market in the coming years. Besides this, forecast figures of the market have been drawn through extensive research analysis methods, for the period of 2019-2026.North America to Emerge Dominant in the Coming YearsBased on regional demographics, the market has been segmented into North America, Latin America, Europe, the middle East and Africa, and Asia Pacific. Among these regions, the market in North America will witness the highest growth in the coming years, driven by easier access to treatment and favourable reimbursement policies. Additionally, the presence of major market players, improving healthcare infrastructure, and growing awareness of blood disorders will have a positive influence on market growth. The ITP market in North America was valued at USD 1.58 Billion in 2018 and is likely to increase further in the coming years.
Sample PDF  https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immune-thrombocytopenia-itp-market-101682

Increasing Number of Mergers and Acquisitions Will Aid Market GrowthThe report encompasses several factors that have contributed to market growth in recent years. As a result of healthy market competition, companies are looking to adopt standout business strategies, with a view to establishing a stronghold. The increasing number of merger and acquisitions have accounted for a significant market growth rate. In 2018, Dova Pharmaceuticals announced a collaboration with Shanghai Fosun Pharmaceuticals for the development and distribution of Doptelet in China and Hong Kong. Similarly, Novartis announced the acquisition of oncology and pipeline department of Glaxo Smith Kline plc. The company plans to extend its business across the world and establish a wider customer reach.List of the leading companies that are operating in the Immune Thrombocytopenia Market are:Amgen Inc.Novartis AGRigel Pharmaceuticals, Inc.Dova PharmaceuticalsGrifols S.ACSL LimitedOctapharma AGIntas Pharmaceuticals Ltd.Saol Therapeutics
Speak to Analyst https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/immune-thrombocytopenia-itp-market-101682

Table of Content:IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsPrevalence of Immune Thrombocytopenia for Key Countries, 2018Introduction of New Products / Approvals (by Major Players)Recent Developments Mergers, Acquisitions and PartnershipsPipeline AnalysisPatent AnalysisGlobal Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026Key Findings / SummaryMarket Analysis, Insights and Forecast – By TypeAcute Immune ThrombocytopeniaChronic Immune ThrombocytopeniaMarket Analysis, Insights and Forecast – By TreatmentThrombopoietin Receptor AgonistsImmunoglobulinsCorticosteroidsOthersMarket Analysis, Insights and Forecast – By Distribution ChannelHospital PharmacyRetail PharmacyOthersMarket Analysis, Insights and Forecast – By CountryNorth AmericaEuropeAsia PacificLatin AmericaMiddle East & AfricaCompetitive LandscapeStrategic RecommendationsContinued…!!!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/immune-thrombocytopenia-itp-market-101682

Browse Related Reports:Revenue Cycle Management Market Size, Share and Global Trend By Structure (In-house Outsource) By Function (Claims & Denial Management, Medical Coding & Billing, Clinical Documentation Improvement (CDI), Insurance, Others) By Type (Software, Services) and Geography Forecast till 2026ePharmacy Market Size, Share and Global Trend By Product (Over-the-Counter Products, Prescription Medicine) and Geography forecast till 2026Breast Implants Market Size, Share & Industry Analysis, By Product (Breast Implants, Tissue Expanders), By Material (Silicone, Saline), By Procedure (Breast Augmentation, Breast Reconstruction), By End User (Hospitals, Specialty Clinics) and Regional Forecast, 2019 – 2026Next-Generation Sequencing (NGS) Market Size, Share and Global Trend By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Geography Forecast till 2026
About us:Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact us:
Fortune Business Insights Pvt. Ltd. 
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
US :+1-424-253-0390
UK :+44-2071-939123
APAC :+91-744-740-1245
Email: sales@fortunebusinessinsights.com
Website: https://www.fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.